RYR2 and catecholaminergic polymorphic ventricular tachycardia: In conclusion, our patient‐derived iPSC‐CM model offers a promising platform for further research into the pathophysiological mechanisms of CPVT, as well as a safe tool for screening and optimizing drug therapy using novel RyR2 inhibitors.